Skip to main content

Advertisement

SpringerLink
Log in

Symptomatic cryoglobulinemia

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

  1. •

    Treatment of symptomatic cryoglobulinemia is exceedingly challenging due to the multisystemic nature of its presentation, the variability of its course, and the paucity of effective therapeutic options supported by randomized controlled clinical trials.

  2. •

    Patients with mild, relatively asymptomatic disease should be observed without introduction of systemic therapy.

  3. •

    Patients with symptomatic type I secondary cryoglobulinemia should be treated as appropriate for their underlying lymphoproliferative or plasmaproliferative disorder.

  4. •

    Patients with secondary type II or type III cryoglobulinemia should be treated for their underlying connective tissue, lymphoproliferative, or liver disorder or infection.

  5. •

    First line treatment for symptomatic, essential type II or type III cryoglobulinemia associated with hepatitis C should include interferon (IFN)-a. Depending on the severity of clinical presentation, adjuvant corticosteroids or plasmapheresis should be considered.

  6. •

    Life-threatening or acute organ-threatening presentations should be managed with combined modality therapy, which should include high-dose corticosteroid, plasmapheresis, or alkylator-based therapy.

  7. •

    Many chemotherapeutic and immunosuppressive strategies have been tried but not systematically tested; their value is therefore unknown.

  8. •

    Challenges for the future of treating symptomatic cryoglobulinemia include devising better therapies and more systematic evaluation of existing therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Meltzer M, Franklin EC, Elias K, et al.: Cryoglobulinemia —a clinical and laboratory study II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966, 40:837–856.

    Article  PubMed  CAS  Google Scholar 

  2. Brouet JC, Clauvel JP, Danon F, et al.: Biological and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974, 57:775–788.

    Article  PubMed  CAS  Google Scholar 

  3. Gorevic PD, Kassab HJ, Levo Y, et al.: Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980, 69:287–308.

    Article  PubMed  CAS  Google Scholar 

  4. Monti G, Saccardo F, Invernizzi F, et al.: Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995, 88:115–126.

    PubMed  CAS  Google Scholar 

  5. Pascual M, Perrin L, Giostra E, et al.: Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990, 162:569–577.

    PubMed  CAS  Google Scholar 

  6. Ferri C, Greco F, Longombardo G, et al.: Antibodies against hepatitis C virus in mixed cryoglobulinemia patients. Infection 1991, 19:417–420.

    Article  PubMed  CAS  Google Scholar 

  7. Ferri C, Moriconi L, Gremignai G, et al.: Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986, 43:246–253.

    PubMed  CAS  Google Scholar 

  8. Invernizzi F, Galli M, Serino G, et al.: Secondary and essential cryoglobulinemias. Frequency, nosological classification, and long-term follow-up. Acta Haematologica 1983, 70:73–82.

    PubMed  CAS  Google Scholar 

  9. Dispenzieri A, Gorevic P: Cryoglobulinemia. Hematol Oncol Clin North Am 1999, 13:1315–1349. Recent extensive review on the pathogenesis, clinical features, and treatment of cryoglobulinemia.

    Article  PubMed  CAS  Google Scholar 

  10. Invernizzi F, Pioltelli P, Cattaneo R, et al.: A long-term follow-up study in essential cryoglobulinemia. Acta Haematol 1979, 61:93–99.

    PubMed  CAS  Google Scholar 

  11. Ferri C, Marzo E, Longombardo G, et al.: Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial. Gut 1993, 34(suppl2):S144-S145.

    Google Scholar 

  12. Misiani R, Bellavita P, Fenili D, et al.: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994, 330:751–756.

    Article  PubMed  CAS  Google Scholar 

  13. Dammacco F, Sansonno D, Han JH, et al.: Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994, 84:3336–3343.

    PubMed  CAS  Google Scholar 

  14. Lauta VM, De Sangro MA: Long-term results regarding the use of recombinant interferon alpha-2b in the treatment of II type mixed essential cryoglobulinemia. Med Oncol 1995, 12:223–230.

    PubMed  CAS  Google Scholar 

  15. Mazzaro C, Lacchin T, Moretti M, et al.: Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 1995, 13:S181-S185.

    PubMed  Google Scholar 

  16. Ferri C, Pietrogrande M, Cecchetti R, et al.: Lowantigen-content diet in the treatment of patients with mixed cryoglobulinemia. Am J Med 1989, 87:519–524.

    Article  PubMed  CAS  Google Scholar 

  17. L’Abbate A, Maggiore Q, Caccamo A, et al.: Long term effects of cryoapheresis and cytostatic treatment in essential mixed cryoglobulinemia. Int J Artif Organs 1985, 2:19–22.

    Google Scholar 

  18. Geltner D, Kohn RW, Gorevic P, et al.: The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum 1981, 24:1121–1127.

    Article  PubMed  CAS  Google Scholar 

  19. Valbonesi M, Montani F, Mosconi L, et al.: Plasmapheresis and cytotoxic drugs for mixed cryoglobulinemia. Haematologia 1984, 17:341–351.

    PubMed  CAS  Google Scholar 

  20. Sinico RA, Fornasieri A, Fiorini G, et al.: Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long-term follow up. Int J Artif Organs 1985, 2:15–18.

    Google Scholar 

  21. D’ Amico G: Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998, 54:650–671. Recent review of cryoglobulinemic glomerulonephritis.

    Article  Google Scholar 

  22. Tarantino A, Campise M, Banfi G, et al.: Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995, 47:618–623.

    Article  PubMed  CAS  Google Scholar 

  23. Bonomo L, Casato M, Afeltra A, et al.: Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987, 83:726–730.

    Article  PubMed  CAS  Google Scholar 

  24. Casato M, Lagana B, Antonelli G, et al.: Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991, 78:3142–3147.

    PubMed  CAS  Google Scholar 

  25. Migliaresi S, Tirri G: Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995, 13:S175-S180.

    PubMed  Google Scholar 

  26. Durand JM, Roubicek C, Retornaz F, et al.: Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998, 25:1115–1117.

    PubMed  CAS  Google Scholar 

  27. Calleja JL, Albillos A, Moreno-Otero R, et al.: Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999, 13:1179–1186.

    Article  PubMed  CAS  Google Scholar 

  28. De Vecchi A, Montagnino G, Pozzi C, et al.: Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 1983, 19:221–227.

    Google Scholar 

  29. Germain MJ, Anderson RW, Keane WF: Renal disease in cryoglobulinemia type II: response to therapy. A case report and review of the literature. Am J Nephrol 1982, 2:221–226.

    PubMed  CAS  Google Scholar 

  30. Ristow SC, Griner PF, Abraham GN, et al.: Reversal of systemic manifestations of cryoglobulinemia. Treatment with melphalan and prednisone. Arch Intern Med 1976, 136:467–470.

    Article  PubMed  CAS  Google Scholar 

  31. Brody J, Samitz M: Cutaneous signs of cryoparaproteinemia: control with burst alkeran and prednisone. Am J Med 1968, 55:211–214.

    Article  Google Scholar 

  32. Ballare M, Bobbio F, Poggi G, et al.: A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia. Clin Exp Rheumatol 1995, 13:S201-S203.

    PubMed  Google Scholar 

  33. Monti G, Saccardo F, Rinaldi G, et al.: Colchicine in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995, 13:S197-S199.

    PubMed  Google Scholar 

  34. Mathison DA, Condemi JJ, Leddy JP, et al.: Purpura, arthralgia, and IgM-IgM cryoglobulinemia with rheumatoid factor activity. Response to cyclophosphamide and splenectomy. Ann Intern Med 1971, 74:383–390.

    PubMed  CAS  Google Scholar 

  35. Meltzer M, Franklin EC: Cryoglobulinemia—a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966, 40:828–856.

    Article  PubMed  CAS  Google Scholar 

  36. Bombardieri S, Ferri C, Paleologo G, et al.: Prolonged plasma exchange in the treatment of renal involvement in essential mixed cryoglobulinemia. Int J Artif Organs 1983, 1:47–50.

    Google Scholar 

  37. Siami GA, Wilkins W, Stone WJ, et al.: Clinical trials of a cryoglobulin filter. ASAIO J 1994, 40:M658-M662.

    Article  PubMed  CAS  Google Scholar 

  38. Pineda A: Applications of therapeutic apheresis. Mayo Clin Proc 1994, 69:894–894.

    Google Scholar 

  39. Ponticelli C, Montagnino G, Campis R, et al.: Treatment of renal disease in essential mixed cryoglobulinemia. In International Milano Meeting of Nephrology: Antiglobulins, Cyroglobulins, and Glomerulonephritis. Milano: Kluwer Academic Publishers; 1985.

    Google Scholar 

  40. Boom BW, Brand A, Bavinck JN, et al.: Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously. Arch Dermatol 1988, 124:1550–1553.

    Article  PubMed  CAS  Google Scholar 

  41. Barton JC, Herrera G, Galla A, et al.: Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987, 82:624–629.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Angela Dispenzieri MD

Authors
  1. Angela Dispenzieri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dispenzieri, A. Symptomatic cryoglobulinemia. Curr. Treat. Options in Oncol. 1, 105–118 (2000). https://doi.org/10.1007/s11864-000-0055-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0055-4

Keywords

Search

Navigation